Introduction {#S0001}
============

Cervical cancer is a growing threat to women's health and remains a main cause of cancer death among women around the world.[@CIT0001] Indeed, cervical cancer was estimated to account for more than 12,000 new cancer cases and 4000 deaths in the United States in 2015.[@CIT0001] Cervical cancer is the seventh most common cancer among women worldwide.[@CIT0002]

Patients with cervical cancer often have a favorable response to radical surgery followed by adjuvant therapy (including platinum-based chemotherapy and radiotherapy).[@CIT0003]--[@CIT0005] Nevertheless, some patients will develop recurrent tumors or will be initially diagnosed as advanced disease. Apart from platinum-resistant cancers, cisplatin or carboplatin plus paclitaxel is an appropriate chemotherapy regimen for these recurrent or advanced tumors.[@CIT0006] Despite its effectiveness, the median progression-free survival (PFS) is only 5.3 months.[@CIT0006] Furthermore, there is no standard regimen for second- and third-line chemotherapy. After failure of multiple lines of chemotherapy, targeted therapy can be an appropriate choice for advanced cervical cancer.[@CIT0007],[@CIT0008] Antiangiogenesis therapy is a common choice for these advanced patients.

Bevacizumab is a monoclonal antibody against the vascular endothelial growth factor (VEGF) and has been widely used against chemotherapy-refractory advanced cervical cancer. When adding bevacizumab to chemotherapy, overall survival (OS), PFS, and tumor response can be improved in cervical cancer patients.[@CIT0009] Nevertheless, its efficacy is still unsatisfactory. Other VEGF receptor (VEGFR) tyrosine kinase inhibitors (including pazopanib, lapatinib, sunitinib) have been seldom used and showed poor efficacy in patients with cervical cancer.[@CIT0010],[@CIT0011]

Apatinib belongs to the first generation of oral antiangiogenesis drug and selectively inhibits VEGFR-2, leading to decreased vascular endothelial cell proliferation and migration, and tumor microvascular density.[@CIT0012] A Phase II trial in advanced or metastatic gastric carcinoma showed that apatinib could improve OS and PFS compared with placebo,[@CIT0013] which was further confirmed by a Phase III trial.[@CIT0014] Several papers indicated that apatinib was an appropriate choice for chemo-refractory malignancies.[@CIT0015]--[@CIT0017]

Although some papers have demonstrated that apatinib was effective and safe for advanced or metastatic gastric cancer, breast cancer, ovarian cancer, lung cancer, and liver cancer,[@CIT0013],[@CIT0014],[@CIT0018]--[@CIT0022] doubts still exist about whether it is an appropriate choice for patients with advanced cervical cancer. Therefore, the aim of this retrospective study was to assess the efficacy and safety of apatinib in advanced cervical cancer patients with ≥2 lines of chemotherapy failure. Although retrospective, this study could suggest novel treatment approach for advanced cervical cancer.

Materials And Methods {#S0002}
=====================

Study Design And Patients {#S0002-S2001}
-------------------------

This was a retrospective study of patients with advanced cervical cancer treated with apatinib between April 2015 and December 2018 at the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. The inclusion criteria were: 1) histopathologically confirmed as cervical squamous cell carcinoma; 2) clinical stage IV; 3) had ≥2 lines of chemotherapy failure; 4) received apatinib alone; and 5) received at least one cycle of apatinib. The exclusion criteria were: 1) prior history of other malignancies or 2) prior history of other antiangiogenic therapies.

This study was approved by the Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Written informed consents were obtained from all the patients before apatinib treatment.

Apatinib Treatment {#S0002-S2002}
------------------

Apatinib (YN968D1, Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) orally administered at an initial dose of 500 mg once daily; if the patient had a body surface \<1.25 m^2^, the starting dose was 250 mg daily. Then, the dose was adjusted according to adverse events and performance status between 250 mg and 850 mg daily. Dose reduction of apatinib resulting from grade 3--4 adverse events was allowed, but was not lower than 250 mg daily. If no grade 2--4 adverse event was observed, the dose of apatinib could be increased from 250 mg to 425 mg or 500 mg daily, or 500 mg to 675 mg or 850 mg daily. One treatment cycle was defined as 28 days (4 weeks). All eligible patients received continuous treatment until disease progression, death, or intolerable toxicity (as determined by their physicians).

Assessment Of Clinical Efficacy {#S0002-S2003}
-------------------------------

PFS was defined as the duration from starting apatinib to disease progression or death. OS was defined as the duration from starting apatinib to death. The objective response rate (ORR) included complete response (CR) and partial response (PR). The disease control rate (DCR) included CR, PR, and stable disease (SD).

The clinical tumor response, determined by assessing the degree of tumor shrinkage, was evaluated after 4 weeks of apatinib treatment, and then every 8 weeks (two cycles). Magnetic resonance imaging (MRI) and/or computed tomography (CT) were performed before and during oral apatinib. The tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.[@CIT0023] RECIST adopts a unidimensional measurement for solid tumors. CR was defined as the disappearance of all target lesions, and all pathological lymph nodes must have decreased to \<10 mm in short axis. PR was defined as at least a 30% decrease in the sum of longest diameters of target lesions, without new lesions. Progressive disease (PD) was defined as at least a 20% increase in the sum of longest diameters of target lesions and ≥5 mm increase above nadir, or the appearance of new lesions. Patients who did not meet the criteria for PR or PD were classified as having SD.

Clinical Assessment For Toxicity {#S0002-S2004}
--------------------------------

Toxicity was analyzed by assessing the incidence of adverse events. The adverse event grades were defined according to the Common Terminology Criteria for Adverse Events of the National Cancer Institute, version 3.0 (CTCAE v3.0).[@CIT0024]

Statistical Analysis {#S0002-S2005}
--------------------

Descriptive statistics were used. Continuous data were presented as mean ± standard deviation or median (range). Categorical data were presented as frequencies. Survival analyses, including OS and PFS, were performed using the Kaplan--Meier method. Data management was performed with SPSS 22.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism, Version 8.0 (GraphPad Software Inc., San Diego, CA, USA).

Results {#S0003}
=======

Characteristics Of The Patients {#S0003-S2001}
-------------------------------

A total of 32 patients with cervical cancer received apatinib alone during the study period, but three were excluded due to treatment duration \<1 month, four were excluded due to being lost to follow up. Finally, 25 patients were included. The characteristics of the patients are shown in [Table 1](#T0001){ref-type="table"}. Six patients experienced dose adjustment during treatment ([Table 2](#T0002){ref-type="table"}). After dose adjustment, 17 patients (68%) received ≥500 mg/day of apatinib.Table 1Patient CharacteristicsCharacteristicsn=25**Age (years)** Median55 Range26--73**ECOG PS (%)** 05 (20) 116 (64) 24 (16)**Stage^a^ at initial diagnosis (%)** I12 (48) II3 (12) III7 (28) IV3 (12)**Site of metastatic disease (%)** Nodes10 (40) Lung13 (52) Liver4 (16) Brain1 (4) Pelvic cavity7 (28) Bone9 (36) Soft tissue1 (4)**No. of sites of metastatic disease (%)** 111 (44) 29 (36) 34 (16) 41 (4)**Histological differentiation (%)** Undifferentiated2 (8) Poorly differentiated6 (24) Moderately differentiated17 (68)**Lines of prior chemotherapy (%)** 2 lines15 (60) 3 lines6 (24) 4 lines4 (16)**Prior radiation (%)** Yes17 (68) No8 (32)**Prior radical surgery (%)** Yes19 (76) No6 (24)[^2][^3] Table 2Dose AdjustmentInitial Dose (%)n=25 250 mg daily3 (12) 500 mg daily22 (88)**Dose adjustment (%)**YesIncrease1 (4)Decrease5 (20)No19 (76)**Final dose** (%) 250 mg daily7 (28) 425 mg daily1 (4) 500 mg daily16 (64) 675 mg daily1 (4)

Clinical Efficacy {#S0003-S2002}
-----------------

The survival time and tumor response are presented in [Table 3](#T0003){ref-type="table"}. The median PFS was 5.8 months (95% CI, 4.65--6.95), and the median OS was 12.2 months (95% CI, 8.99--15.41) ([Figure 1](#F0001){ref-type="fig"}). ORR was 48% and DCR was 96%. Of note, CR was not observed. Decrease of tumor size occurred in 21 patients (84%) ([Figure 2](#F0002){ref-type="fig"}).Table 3Efficacy Of Apatinib In Patients With Cervical Cancern=2595% CI**Median PFS (months)**5.84.65--6.95**Median OS (months)**12.28.99--15.41**Tumor response** PR (%)12 (48) SD (%)12 (48) PD (%)1 (4)**ORR**48%**DCR**96%[^4] Figure 1Kaplan--Meier curve of progression-free survival (**A**) and overall survival (**B**). Red-dotted lines represent 95% confidence intervals (CIs).Figure 2Waterfall plot for the best percentage change in the sum of longest diameters of target lesions from baseline.

Adverse Events {#S0003-S2003}
--------------

[Table 4](#T0004){ref-type="table"} presents the treatment-related adverse events that were observed among all 25 patients. Most adverse events were mild and manageable and there was no adverse event associated with death. The grade 3/4 treatment-related adverse events were hand-foot syndrome (n=3, 12%), mouth mucositis (n=1, 4%), and thrombocytopenia (n=1, 4%). The most common adverse events in this study (all grades) were hand-foot syndrome (n=12, 48%), hypertension (n=5, 20%), and mouth mucositis (n=5, 20%). Dose reduction occurred in five patients due to adverse events. One patient refused oral apatinib after 3 months of treatment, due to grade 4 hand-foot syndrome.Table 4Adverse Events Based On Treatmentn=25Any GradeGrade 3/4Hypertension (%)5 (20)0Proteinuria (%)4 (16)0Hand-foot syndrome (%)12 (48)3 (12)Mouth mucositis (%)5 (20)1 (4)Bleeding (%)1 (4)0Fatigue (%)3 (12)0Abdominal pain (%)1 (4)0Decreased appetite (%)2 (8)0Thrombocytopenia (%)1 (4)1 (4)

Typical Case {#S0003-S2004}
------------

A 43-year-old female patient with advanced cervical cancer and with failure to 3 lines of chemotherapy received apatinib at 500 mg daily in September 2015. From September 2015 to June 2016, the longest diameter of the retroperitoneal lesion decreased from 33 to 23 mm and lung metastases also shrunk significantly or disappeared ([Figure 3](#F0003){ref-type="fig"}), which was defined as PR. Serum squamous cell carcinoma (SCC) antigen decreased from 52.9 to 24.8 μg/L. The patient only suffered from grade 2 hand-foot syndrome. Disease progression occurred on November 2016 and serum SCC antigen increased to 65.7 μg/L. Then, the patient stopped to use apatinib.Figure 3(**A1-2**) Computed tomography (CT) scan before apatinib treatment (September 2015). (**B1-2**) CT scan after 1 month of apatinib treatment (October 2015). (**C1-2**) CT scan after 10 months of apatinib treatment (June 2016). The longest diameters of the retroperitoneal lesions (red arrows) were 33 mm (**A1**), 25 mm (**B1**), and 23 mm (**C1)**. From **A2** to **C2**, lung metastases (red arrows) shrunk significantly or disappeared.

Discussion {#S0004}
==========

Cervical cancer is a common female malignancy. The early-staged patients will have favorable outcomes,[@CIT0003]--[@CIT0005] while advanced ones will have poor prognosis.[@CIT0025] Antiangiogenesis therapy is common for advanced cervical cancer, but with limited efficacy.[@CIT0009]--[@CIT0011] Therefore, to find a new, effective and safe targeted drug for these patients is a matter of urgency for improving treatment outcomes.

VEGF and VEGFR-2 play an essential role in tumor angiogenesis.[@CIT0026] Apatinib (formerly known as YN968D1) targets VEGFR-2, RET, platelet-derived growth factor-β (PDGFR-β), c-Src, and c-Kit.[@CIT0027],[@CIT0028] According to in vitro experiments, apatinib is an even more selective inhibitor of VEGFR-2 than sunitinib, with an IC50 of 0.001 lM and 0.005 lM, respectively.[@CIT0012] Apatinib can effectively inhibit the proliferation, migration, and tube formation of human umbilical vein endothelial cells, can block the budding of rat aortic ring, and can inhibit the growth of several established human tumor xenograft models with little toxicity.[@CIT0012] Previous studies reported that apatinib could reverse ATP-binding cassette transporter (ABC) subfamily B member 1 (MDR1/P-glycoprotein) and ABC subfamily G member 2 (BCRP)-mediated multidrug resistance, which leads to potential usefulness of combining apatinib with other chemotherapy drugs.[@CIT0027],[@CIT0029]

In a Phase I trial, apatinib has shown encouraging antitumor activity (18.9% of PR and 64.9% of SD) and a manageable toxicity profile in patients with advanced solid malignancies, including gastric, colorectal, lung, and breast cancers.[@CIT0030] The efficacy and safety of apatinib were further confirmed in advanced or metastatic gastric cancer, breast cancer, ovarian cancer, lung cancer, and liver cancer by recent clinical trials.[@CIT0013],[@CIT0014],[@CIT0018]--[@CIT0022] These data suggest that apatinib was a favorable choice as rescue therapy for the advanced patients with ≥2 lines of chemotherapy failure. Nevertheless, the therapeutic value of apatinib in cervical cancer is still unknown. In the present study, apatinib showed median PFS, median OS, ORR, and DCR of 5.8 months, 12.2 months, 48%, and 96%, respectively, which were not worse than the data observed in other malignancies.[@CIT0014],[@CIT0018],[@CIT0019],[@CIT0022]

The efficacy and safety of bevacizumab have been proven by several clinical trials. In a Phase II trial, patients with persistent or recurrent cervical cancer treated with bevacizumab, achieved median PFS of 3.4 months, median OS of 7.3 months, and ORR of 11% (no CR and five PR, total 46 patients), respectively.[@CIT0031] Patients with platinum-resistant cervical cancer can also benefit from bevacizumab.[@CIT0032]

Other VEGFR tyrosine kinase inhibitors (including pazopanib, lapatinib, and sunitinib) were seldom used in cervical cancer. In clinical trials of advanced or recurrent cervical cancer, median PFS of pazopanib, lapatinib, and sunitinib were 18.1 weeks, 17.1 weeks, and 3.5 months, respectively; median OS of pazopanib and lapatinib were 50.7 and 39.1 weeks, respectively; ORRs of pazopanib, lapatinib, and sunitinib were 9.5%, 5.1%, and 0%, respectively; and DCRs of pazopanib, lapatinib, and sunitinib were 52.7%, 48.7%, and 84.2%, respectively.[@CIT0010],[@CIT0011] The comparison between apatinib and other antiangiogenesis drugs is shown in [Table 5](#T0005){ref-type="table"}.Table 5Comparison Between Apatinib And Other Antiangiogenesis DrugsLines Of Prior ChemotherapynmPFS (Months)mOS (Months)ORR (%)DCR (%)ReferenceApatinib≥ 2 lines255.812.24896Present studyBevacizumab1 or 2 lines463.47.311[@CIT0031]Pazopanib0, 1, or 2 lines7818.1 weeks50.7 weeks9.552.7[@CIT0010]Lapatinib0, 1, or 2 lines7417.1 weeks39.1 weeks5.148.7[@CIT0010]Sunitinib0, 1, or 2 lines193.5084.2[@CIT0011][^5]

The most common treatment-related adverse events of apatinib in this study were hand-foot syndrome (48%), hypertension (20%), and mouth mucositis (20%), which were similar to those reported in other malignancies.[@CIT0014],[@CIT0018],[@CIT0019],[@CIT0022] During oral apatinib treatment, five patients received dose reductions and one patient discontinued treatment due to treatment-related adverse events. Other patients experienced mild and manageable adverse events.

The present study has two limitations. First, the number of patients was small and clinical significance was limited. The next step will be to further expand the number of patients. Secondly, this was a retrospective study. A multicenter randomized controlled study focusing on this issue is warranted.

Conclusion {#S0005}
==========

In this study, apatinib monotherapy showed good therapeutic value with tolerable adverse events for patients with chemo-refractory advanced cervical cancer. The feasibility of apatinib combined with chemotherapy in advanced cervical cancer should be further confirmed in future studies.
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